H
Loading...
Loading...
CDC PLACES (2023, crude) estimates 11.5% of adults in Providence have diagnosed diabetes — 0.5 points below the U.S. 12% figure. Census population 189,692. Rhode Island Medicare wound biologics: National Government Services (NGS) (JK). Hawk Medical is a national HCT/P 361 and wound-care distributor serving licensed Providence clinics — not a walk-in office.
Written for licensed providers. Reviewed by Joe Bradley, Founder & CEO. Content version 2026-09-18. Hawk Medical ships nationwide — this is not a Providence storefront.
Fibrin Matrix Therapy Products in Providence, RI for clinics & physicians. Fibrin matrix therapy supports… Compliance support & pricing — contact Hawk Medical.
Adult obesity in Providence is 34.4% (CDC PLACES 2023). That shows up in wound offloading and in joint-preservation volume — not as a slogan. CDC PLACES (2023, crude) estimates 11.5% of adults in Providence have diagnosed diabetes — 0.5 points below the U.S. 12% figure. Rhode Island is outside CDC’s core Diabetes Belt list; use the PLACES city rate anyway. Hawk Medical is the distributor for fibrin matrix therapy, not a walk-in clinic.
National Fibrin Matrix Therapy Products notes (how the product actually works)America’s Health Rankings (BRFSS 2024) only publishes state diabetes as a range nationally (Colorado 8.4% to West Virginia 18.4%). For Providence we use CDC PLACES instead of interpolating a fake city rate from that range. CDC PLACES (2023, crude) estimates 11.5% of adults in Providence have diagnosed diabetes — 0.5 points below the U.S. 12% figure.
If you already buy fibrin matrix therapy elsewhere, use this page as a check: homologous-use language, current National Government Services (NGS) article IDs, and PLACES 11.5% diabetes as the epidemiologic floor. If that is how you already practice, the catalog will fit.
CDC PLACES (2023, crude prevalence) estimates 11.5% of adults — 0.5 points below the U.S. 12% figure. Obesity is 34.4%; arthritis is 18.8%. That is place-level BRFSS modeling, not a clinic census and not a Providence trial.
The 96.5% figure is a product-level clinical experience statistic published on our wound-care materials — not a city-specific trial. Your outcomes will depend on patient selection, offloading, and follow-up.
No. PRP (autologous) and cellular/tissue products (allograft/skin substitutes) sit on different coding and coverage paths. National Government Services (NGS) LCDs for CTPs do not automatically cover PRP injections. Build separate protocols and fee tickets.
We distribute nationwide. Transit time depends on carrier and SKU, not on a fictional local warehouse. Ask for current lead times on the specific centrifuge, allograft, or CTP you intend to bill.
If you operate in Rhode Island and another MAC state, say it on the first call. JK will not port 1:1. We would rather split utilization than watch a sister clinic copy Providence tickets into the wrong jurisdiction.
Contact us to learn how Hawk Medical supports practices in Providence, RI.
Hawk Medical is a national distributor. Joe Bradley’s clinic uses the same product classes. What is local for Providence is JK geography and published epidemiology — not a street address.
CDC PLACES 2023 crude rate for Providence — 0.5 points below the U.S. 12% figure. Planning input, not an outcomes claim.
Rhode Island Part B wound biologics follow this contractor (siblings: CT, MA, ME, NH, NY, VT). We train to the articles. We do not write coverage.
PLACES crude adult arthritis in Providence. Useful for joint-program math; still needs a diagnosis and privileging.
No Providence storefront. Joe Bradley is an active practice owner. fibrin matrix therapy stays in its regulatory lane — not “FDA-approved stem cell therapy.”
Experience the difference of working with a distributor who understands your practice because we operate one ourselves.